Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced Unresectable NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 0 results

Large-scale testing (Phase 3)Study completedNCT04513925
What this trial is testing

Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche 829
Testing effectiveness (Phase 2)Study completedNCT02709720
What this trial is testing

Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC

Who this might be right for
Lung Cancer
Spanish Lung Cancer Group 68
Testing effectiveness (Phase 2)Ended earlyNCT00271323
What this trial is testing

Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients

Who this might be right for
Non-Small-Cell Lung Carcinoma
Sanofi 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT06003231
What this trial is testing

Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Who this might be right for
Carcinoma, Non-Small-Cell LungOvarian NeoplasmsEndometrial Neoplasms+1 more
Seagen, a wholly owned subsidiary of Pfizer 120
Testing effectiveness (Phase 2)Looking for participantsNCT05706129
What this trial is testing

Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Clear Cell Renal Cell Cancer (ccRCC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)+6 more
Lumara Bio Oncologics GmbH 270
Early research (Phase 1)Study completedNCT04672434
What this trial is testing

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Who this might be right for
Metastatic CancerSolid Tumor
Symphogen A/S 48
Not applicableActive Not RecruitingNCT05887011
What this trial is testing

CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia

Who this might be right for
Unresectable /Inoperable Locally Advanced (Stage II-III) NSCLC and Locally Advanced LS-SCLC (Stage I-III)
AstraZeneca 2,000
Testing effectiveness (Phase 2)UnknownNCT01158144
What this trial is testing

Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902)

Who this might be right for
Non-small Cell Lung Cancer
Zhejiang Cancer Hospital 134
Early research (Phase 1)Active Not RecruitingNCT04676477
What this trial is testing

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Daiichi Sankyo 246
Not applicableActive Not RecruitingNCT05456867
What this trial is testing

A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia

Who this might be right for
NSCLC, Non-small-cell Lung Carcinoma
AstraZeneca 250
Testing effectiveness (Phase 2)Study completedNCT01000480
What this trial is testing

Pemetrexed and Cisplatin, in Non Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Eli Lilly and Company 90
Testing effectiveness (Phase 2)Study completedNCT00356122
What this trial is testing

Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Sanofi 53
Early research (Phase 1)Active Not RecruitingNCT04013542
What this trial is testing

Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer

Who this might be right for
ALK Gene RearrangementEGFR Gene MutationLocally Advanced Lung Non-Small Cell Carcinoma+9 more
M.D. Anderson Cancer Center 21
Early research (Phase 1)Looking for participantsNCT07589205
What this trial is testing

Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors

Who this might be right for
Solid TumorColorectal CancerNon-small Cell Lung Cancer+2 more
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. 493
Not applicableStudy completedNCT04285866
What this trial is testing

Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.

Who this might be right for
Small Cell Lung Cancer (SCLC)
Fundación GECP 245
Early research (Phase 1)Study completedNCT02572687
What this trial is testing

Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaNon-Small Cell Lung Cancer+1 more
Eli Lilly and Company 85